Eli Lilly and Company (BMV:LLY)

Market Cap	13.88T
Revenue (ttm)	1.00T
Net Income (ttm)	260.24B
Shares Out	n/a
EPS (ttm)	288.39
PE Ratio	53.32
Forward PE	29.65
Dividend	114.81 (0.74%)
Ex-Dividend Date	Aug 15, 2025

Volume	458
Average Volume	1,454
Open	15,802
Previous Close	15,670
Day's Range	15,450 - 15,802
52-Week Range	11,630 - 19,204
Beta	0.46
RSI	68.11
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD